Login with Linked

Follow us on

Link Linkedin Youtube

Ojemda

Ojemda is the first FDA-approved targeted therapy for children 6 months and older with relapsed or treatment-resistant pediatric low-grade glioma (pLGG) caused by certain BRAF gene changes.

Molecule Details :

  • Molecule Name :

    Tovorafenib

  • Innovator :

    DAY ONE BIOPHARMACEUTICALS INC

  • Approval Date :

    23-Apr-24

  • NCE-1 Date :

    23-Apr-28

  • NCE Date :

    23-Apr-29

  • Dosage Form :

    Oral Suspension

  • Strength :

    25MG-ML

  • Therapeutic Category :

    Anticancer

  • Revenue ($M) :

    57

Year-wise Projected Sales ($M) :

  • 2025 :

    156

  • 2026 :

    255

  • 2027 :

    363

  • 2028 :

    497

  • 2029 :

    641

  • 2030 :

    779

  • 2031 :

    924
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.
Request a Quote

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Schedule a Call With Us
Login with Linked

Follow us on

Linkedin Youtube Link

Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?

Not Now
Logout
Need your comparator insight?